Recursion Pharmaceuticals

US · RXRX #2649 by market cap Listed 2021

4.27 -0.36 -7.78%

Live - 5344 symbols - heartbeat 33s ago · 2026-10-08 07:00

Pre-market 4.19 -1.91%

After-hours 4.27 0.00%

Overnight 4.26 -0.23%

Market cap: 2.29B
P/E (TTM): -4.27
P/B: 2.50
EPS: -1.44
Div yield: 0.00%
52W pos: 34%

Reader sentiment Are you bullish or bearish on RXRX?

Anonymous reader poll. Unscientific, not investment advice.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Founded: 2013
CEO: Dr. Najat Khan, PhD
Employees: 600
Headquarters: Salt Lake City, Utah, United States of America
Fiscal year end: 12-31
Website: recursion.com

Company profile

Exchange: US
Symbol: RXRX
Market-cap rank: #2649
Listing date: 2021-04-16
Market cap: 2.29B
Float cap: 2.19B
Shares out: 535.34M
Float shares: 512.98M

Sectors & themes

Biotechnology ARK Portfolio AI medical concept stocks Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 07:00:30 · For reference only, not investment advice and not tailored to your situation.